Copyright
©The Author(s) 2019.
World J Hepatol. Nov 27, 2019; 11(11): 735-742
Published online Nov 27, 2019. doi: 10.4254/wjh.v11.i11.735
Published online Nov 27, 2019. doi: 10.4254/wjh.v11.i11.735
Table 1 Laboratory testing done to investigate acute liver failure etiology
| Laboratory test | Reference range | Results |
| Liver function tests | ||
| Alanine aminotransferase | 15-41 U/L | 981 (H) |
| Aspartate aminotransferase | 3-34 U/L | 1062 (H) |
| Alkaline phosphate | 45-117 U/L | 248 (H) |
| Total bilirubin | 0.2-1.3 mg/dL | 1.3 (N) |
| Conjugated bilirubin | 0.0-0.30 mg/dL | 0.73 (H) |
| Total Protein | 6.3-8.2 g/dL | 6.8 (N) |
| Albumin | 3.5-5.0 g/dL | 2.8 (L) |
| Ammonia level | 0-32 μmol/L | 44 (H) |
| Coagulation Studies | ||
| Prothrombin time | 10-13.5 s | 19.0 (H) |
| International normalized ration | 0.8-1.2 | 1.6 (H) |
| Viral serologies | ||
| Hepatitis A, IgM | Nonreactive | Nonreactive |
| Hepatitis A, IgG | Nonreactive | Reactive |
| Hepatitis B, core IgM | Nonreactive | Nonreactive |
| Hepatitis B, surface antigen | Nonreactive | Nonreactive |
| Hepatitis C antibody | Nonreactive | Nonreactive |
| Human immunodeficiency virus 1 and 2 antibody/antigen | Nonreactive | Nonreactive |
| Herpes simplex virus 1 and 2 IgM | Negative | Negative |
| Cytomegalovirus, IgM | Negative | Negative |
| Cytomegalovirus, IgG | Negative | Negative |
| Epstein Barr virus, IgM | Negative | Negative |
| Parvovirus B19, IgM/IgG | Negative | Negative |
| Rapid plasma regain (RPR) | Nonreactive | Nonreactive |
| Influenza A, antigen | Negative | Negative |
| Influenza B, antigen | Negative | Positive |
| Autoimmune liver disease panel | ||
| Antinuclear antibody | Negative | Negative |
| Antinuclear antibody titer | < 1.0 U | 0.6 (N) |
| Antismooth muscle antibody | Negative | Negative |
| Antimitochondrial antibody, M2 | < 0.1 U | < 0.1 (N) |
| Toxicology studies | ||
| Acetaminophen level | 10-30 mcg/ml | < 2 |
| Ethanol level | 0-3 mg/dL | < 3 |
| Urine toxicology screen | Negative | Negative |
Table 2 Case reports of hepatotoxicity related to non-Hydroxycut formulation of Garcinia cambogia since 2009
| Case report | Year | Age | Sex | Duration of GC use | Clinical presentation | CIOSM/RUCAM score | Liver transplantation |
| Present case | 2019 | 26 | Female | 28 d | Nausea, vomiting, abdominal pain, anorexia and myalgia | 9 | No |
| Sharma et al[15] | 2018 | 57 | Female | 28 d | Vomiting and abdominal pain | 11 | No |
| Kothadia et al[14] | 2018 | 36 | Female | 28 d | Fever, nausea, vomiting, abdominal pain, fatigue and jaundice | 8 | No |
| Lunsford et al[7] | 2016 | 34 | Male | 150 d | Nausea, vomiting, abdominal pain and dark urine | NA | Yes |
| Smith et al[13] | 2016 | 26 | Male | 7 d | Fatigue, icteric sclera and skin | 6 | Yes |
| Corey et al[12] | 2016 | 52 | Female | 25 d | Fatigue, intermittent confusion and jaundice | 7 | Yes |
| Melendez-Rosado et al[11] | 2015 | 42 | Female | 7 d | Nausea, abdominal pain, clamminess | NA | No |
| Lee et al[16] | 2014 | 39 | Female | 2 d | Nausea, abdominal pain, anorexia, dyspepsia, fatigue and jaundice | 9 | No |
| Sharma et al[10] | 2010 | 19 | Male | NA | Fever, fatigue, myalgia, arthralgia, Nausea, Vomiting, abdominal pain and jaundice, erythematous skin rash lower extremities | 7 | No |
Table 3 The Council of International Organizations of Medical Sciences and Roussel Uclaf Causality Assessment Method Scale
| Criteria | Score |
| Time from drug intake until reaction onset | |
| 5-90 d | +2 |
| < 5 or > 90 d | +1 |
| Time from drug withdrawal until reaction onset | |
| < 15 d | +1 |
| > 15 d | 0 |
| Alcohol risk | |
| Present | +1 |
| Absent | 0 |
| Age | |
| > 55 yr | +1 |
| < 55 yr | 0 |
| Course of reaction | |
| > 50% improvement within 8 d | +3 |
| > 50% improvement within 30 d | +2 |
| Worsening or < 50% improvement in 30 d | -1 |
| Concomitant therapy | |
| Time to onset incompatible | 0 |
| Time to onset compatible but with unknown reaction | -1 |
| Time to onset compatible but known reaction Role proved in the case | -2 -3 |
| None or information not available | 0 |
| Exclusion of non-drug related causes | |
| Ruled out | +2 |
| Possible or not investigated | 0 |
| Probable | -3 |
| Previous information on hepatotoxicity | |
| Reaction unknown | 0 |
| Reaction published but unlabeled | +1 |
| Reaction labeled in the product’s characteristics | +2 |
| Response to re-administration | |
| Positive | +3 |
| Compatible | +2 |
| Negative | -2 |
| Not available or not interpretable | 0 |
| Plasma concentration of drug known as toxic | +3 |
| Validated laboratory test with high specificity, sensitivity, and predictive values positive | +3 |
| Validated laboratory test with high specificity, sensitivity, and predictive values negative | -3 |
| Interpretation of score for drug induced liver injury: | |
| > 8 definite drug induced liver injury | |
| 6-8 probable drug induced liver injury | |
| 3-5 Possible drug induced liver injury | |
| 1-2 Unlikely drug induced liver injury | |
| < 0 drug induced liver injury excluded |
- Citation: Yousaf MN, Chaudhary FS, Hodanazari SM, Sittambalam CD. Hepatotoxicity associated with Garcinia cambogia: A case report. World J Hepatol 2019; 11(11): 735-742
- URL: https://www.wjgnet.com/1948-5182/full/v11/i11/735.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i11.735
